A retrospective study assessing the clinical value of inflammation-based biomarkers in pleural Mesothelioma during immunotherapy
Latest Information Update: 16 Sep 2022
At a glance
- Drugs Atezolizumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Antineoplastics
- Indications Malignant-mesothelioma
- Focus Pharmacodynamics; Therapeutic Use
Most Recent Events
- 16 Sep 2022 New trial record
- 09 Aug 2022 Results presented at the 2022 World Conference on Lung Cancer